Patents by Inventor Bharathikumar Vellalore Maruthachalam

Bharathikumar Vellalore Maruthachalam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR POLYMERIC ANTIBODY RECEPTOR TARGETING
    Publication number: 20230019640
    Abstract: VHH domains that bind to p1gR are described. The VHH domain may compete with IgA binding to p1gR, or alternatively, the VHH domain may compete with IgA binding to p1gR. The VHH domains may be coupled to therapeutic agents so as to facilitate delivery of the therapeutic agent to the mucosal layer via p1gR-mediated transcytosis. The therapeutic agent can be a small molecule, large molecule, or even an antibody.
    Type: Application
    Filed: July 31, 2020
    Publication date: January 19, 2023
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Adam ZWOLAK, Brian GEIST, Xiefan LIN-SCHMIDT, Sathyadevi VENKATARAMANI, Sanjaya SINGH
  • MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION
    Publication number: 20220324970
    Abstract: A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.
    Type: Application
    Filed: July 31, 2020
    Publication date: October 13, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Adam ZWOLAK, Brian GEIST, Xiefan LIN-SCHMIDT, Sathyadevi VENKATARAMANI, Sanjaya SINGH
  • CHIMERIC ANTIGEN RECEPTOR SYSTEM AND USES THEREOF
    Publication number: 20220305056
    Abstract: Provided herein are chimeric antigen receptors (CARs), cells comprising the CARs, monoclonal and bispecific antibodies or antigen-binding fragments thereof, and kits comprising the same. The CARs and bispecific antibodies are designed to target at least one tumor antigen and at least one tumor in methods of treating cancer in subjects in need thereof.
    Type: Application
    Filed: August 26, 2020
    Publication date: September 29, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Bharathikumar Vellalore MARUTHACHALAM, Sathyadevi VENKATARAMANI, Iqbal GREWAL, Sanjaya SINGH, Paul HARVILLA, Martin Jack BORROK III, Ninkka TAMOT, Yonghai LI
  • HER3 binding agents and uses thereof
    Patent number: 11390686
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: July 19, 2022
    Assignee: University of Saskatchewan
    Inventors: Bharathikumar Vellalore Maruthachalam, Ayman Elsayed Mohammad, Jianghai Liu, Humphrey Fonge, Kris Barreto, Clarence Ronald Geyer
  • HER3 BINDING AGENTS AND USES THEREOF
    Publication number: 20200207868
    Abstract: The disclosure is directed to antibodies and binding fragments thereof that specifically bind HER3. The disclosure is further directed to immunoconjugates comprising the antibodies and binding fragments thereof that specifically bind HER3. The disclosure is also directed to uses of the antibodies, binding fragments thereof and immunoconjugates for detecting HER3-expressing cells and for treating HER3-expressing cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: July 2, 2020
    Inventors: Bharathikumar Vellalore Maruthachalam, Aynan Elsayed Mohammad, Jianghai Liu, Humphrey Fonge, Kris Barreto, Clarence Ronald Geyer